|Products & Services
|CryoValve® Aortic Valve Allograft|
Visit TheIdealValve.com to learn why CryoValve is The Ideal Valve for endocarditis.
While there are many prosthetic heart valve replacement devices available today, few can offer the same benefits to recipients as the CryoLife CryoValve. Supported by clinical data1,2 and the experience of the medical community, CryoValve’s flexibility and natural handling qualities make it an ideal replacement option.
CryoValve, with its documented durability and resistance to infection, provides surgeons with an aortic valve allograft for valve replacement and procedures involving root reconstruction. With CryoValve, patients can resume an active lifestyle without anticoagulant limitations and with a minimal risk of re-infection.
As human tissue, CryoValve is the ideal replacement for extensive native and prosthetic valve endocarditis3 because of its inherent resistance to reinfection. In addition, the attached anterior mitral leaflet remnant is available to cover even the most extensive excavations and perforations. As a valved conduit, which includes the entire ascending aorta and arch, it is an excellent choice for combined disease of the aortic valve and aortic root, which is very common in patients with a congenital unicuspid or bicuspid aortic valve. It is ideal for the treatment of aortic dissection involving the sinus portion of the aorta where a composite graft replacement of the aortic valve and root is typically used. It is also a preferred option for patients requiring aortic valve replacement who need to avoid prosthesis-patient mismatch or anticoagulation. As a true stentless valve, it allows for an unobstructed left ventricular outflow tract and the attendant advantages of normal physiology. Since the anterior mitral leaflet and ascending aorta are included, it is a highly versatile replacement option, with the unique handling characteristics of human tissue.
1 O’Brien M.F. et al. The homograft aortic valve: A 19-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Disease 2001; 10: 334-345.